Ovarian Cancer Risk Assessment & Screening Tool | Dr. Lalita Vaitheeswaran

👥 Target Population Identification

Routine population-wide screening is NOT recommended. Risk-stratified targeting is the evidence-based approach (ACOG, RCOG, NCCN).

⚡

Key Clinical Insight: Unlike cervical cancer, ovarian cancer lacks an effective population-wide screening program. Screening should be risk-based, focused on high-risk groups, with strong emphasis on symptom awareness and early referral.

🔴 HIGH-RISK GROUPS — Targeted Screening Warranted

BRCA1 mutation carriers — Lifetime risk: 39–46% (NCCN 2024)
BRCA2 mutation carriers — Lifetime risk: 12–20%
Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) — Risk: 6–12%
Strong family history — ≥2 first-degree relatives with ovarian/breast cancer
BRIP1, RAD51C, RAD51D mutation carriers (moderately elevated risk)
Prior history of breast cancer diagnosed <50 years
Hereditary Breast-Ovarian Cancer (HBOC) syndrome families

BRCA1/2 Lynch Syndrome Genetic Mutation

🟠 INTERMEDIATE-RISK GROUPS — Enhanced Surveillance

One first-degree relative with ovarian cancer
Family history of breast + ovarian cancer (same lineage)
Age >40 years with multiple risk factors
Postmenopausal women with new pelvic mass
Personal history of endometriosis (3× risk increase)
Nulliparous women aged >50 years

Age >40 Family Hx Endometriosis

🔵 AVERAGE-RISK POPULATION — No Routine Screening

General population women without high-risk features
Lifetime risk ~1.3% (general population)
Annual symptom awareness education recommended
Opportunistic pelvic examination at routine gynae visits
Routine CA-125 or TVUS NOT recommended (USPSTF Grade D, 2018)

General Population Symptom Awareness

📅 Age Stratification Framework

Age Group	Risk Level	Recommendation
<40 years	Low	Symptom awareness; genetic testing if BRCA family history
40–50 years	Moderate	Risk assessment; BRCA testing if indicated; consider TVUS if high-risk
50–70 years	Moderate-High	Active surveillance if risk factors; CA-125 + TVUS annually for BRCA carriers
>70 years	High	Clinical vigilance; evaluate all new pelvic masses urgently
Postmenopausal	Elevated	Any pelvic mass = urgent investigation; CA-125 + imaging

📊 Epidemiology & Context (India & Global)

Global incidence: ~313,959 new cases/year (WHO 2020)
India: 8th most common cancer in women; ASR ~6.2/100,000
5-year survival (all stages): ~49% globally; ~30–40% in India
Stage at diagnosis: ~70% diagnosed at Stage III/IV (late)
Stage I 5-yr survival: >90%; Stage IV: ~29%
Epithelial ovarian cancer: 90% of all malignant ovarian tumours
Peak incidence: 55–65 years (postmenopausal)

💡

Indian Context (NCRP/ICMR): No national ovarian cancer screening program exists. Indian Council of Medical Research (ICMR) guidelines align with FIGO and ACOG — risk-based screening only. Genetic testing availability remains limited but expanding.

🧪 Screening Modalities & Protocols

Evidence-based screening strategies as per IOTA, ACOG, RCOG, and NICE guidelines. No single modality has proven survival benefit in average-risk women.

🩸 A. Blood-Based Biomarkers

🔬 CA-125 (Cancer Antigen 125)

Normal: <35 U/mL (premenopausal); <20 U/mL (postmenopausal)
Sensitivity: ~79% for early-stage; ~92% for advanced disease
Specificity: Low in premenopausal (benign causes common)
Elevated in: endometriosis, fibroids, PID, pregnancy, liver disease
Best utility in postmenopausal women with pelvic mass
Used in ROCA (Risk of Ovarian Cancer Algorithm) for longitudinal monitoring

⚠️

Limitation: Elevated in only 50% of Stage I ovarian cancer. USPSTF advises against routine CA-125 in average-risk women (Grade D).

🔬 HE4 (Human Epididymis Protein 4)

Cutoff: <70 pmol/L (premenopausal); <140 pmol/L (postmenopausal)
Higher specificity than CA-125; less affected by benign conditions
Not elevated in endometriosis, fibroids, or pregnancy
FDA-approved for monitoring recurrence (2008)
Best used in combination with CA-125

📊 ROMA Score (Risk of Ovarian Malignancy Algorithm)

Combines CA-125 + HE4 + menopausal status
High risk: ROMA ≥13.1% (premenopausal) / ≥27.7% (postmenopausal)
AUC ~0.91 for discriminating malignancy from benign mass
Better performance than either marker alone
Recommended by ESMO and SIGN guidelines for adnexal mass triage

🧬 ROCA (Risk of Ovarian Cancer Algorithm)

Longitudinal CA-125 algorithm measuring rate of change
Used in UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening)
Triages to: normal → repeat in 12 months; intermediate → TVUS; elevated → refer
Showed ~40% stage shift in UKCTOCS (N=202,638) — mortality data awaited

🔬 Emerging Biomarkers (Research Phase)

OVA1® & Overa® — multivariate index assays
ctDNA / liquid biopsy — circulating tumour DNA
microRNA panels — miR-200 family
Mesothelin, CEA, CA19-9 — adjunctive markers
Not yet standard of care; clinical trials ongoing

🖥️ B. Imaging Modalities

🔊 Transvaginal Ultrasound (TVUS)

First-line imaging for pelvic mass evaluation (RCOG, ACOG)
Evaluates: size, morphology, cyst complexity, solid areas, septae, vascularity
IOTA simple rules: classify as B-features (benign) vs M-features (malignant)
ADNEX model (IOTA): estimates probability of malignancy
Sensitivity ~75-85%; Specificity ~65-70% for malignancy
Combined with CA-125: sensitivity improves to ~88-92%

📌

IOTA Classification: Simple cyst, mucinous, dermoid, fibroma = likely benign. Solid irregular mass, ascites, bilateral lesions = suspicious.

📷 MRI Pelvis with Contrast

Superior soft tissue characterisation of adnexal masses
Recommended when TVUS is inconclusive (ESUR, RCOG)
O-RADS MRI scoring: 1–5 scale for malignancy risk
Best for complex masses, endometrioid cysts, borderline tumours
No radiation; preferred in young women and pregnancy

🔍 CT Abdomen & Pelvis

NOT primary screening tool — used for staging & surgical planning
Evaluates: peritoneal disease, lymphadenopathy, distant metastases
Recommended when ovarian cancer suspected clinically
CT-guided biopsy for unresectable disease

☢️ PET-CT

Used for recurrence detection and therapy response monitoring
Not recommended as primary screening modality
Indicated: rising CA-125 with negative conventional imaging

📅 Screening Protocol by Risk Group

Risk Group	Modality	Frequency	Guideline
Average risk	None recommended	—	USPSTF D, ACOG
BRCA1 carriers	CA-125 (ROCA) + TVUS Risk-reducing BSOPSO preferred	Every 6 months (age 30–35+)	NCCN 2024, RCOG
BRCA2 carriers	CA-125 + TVUS	Every 6 months (age 35–40+)	NCCN 2024
Lynch syndrome	Consider CA-125 + TVUS Evidence weak	Annual (from age 30–35)	NCCN, ESMO
Strong family history	CA-125 + TVUS	Annual	RCOG 2023
Postmenopausal pelvic mass	TVUS + CA-125 + ROMA	Urgent (2-week wait pathway)	NICE NG12, RCOG

⭐

UKCTOCS Trial (2021, N=202,638): Multimodal screening with ROCA + TVUS did not significantly reduce ovarian cancer mortality at 14-year follow-up. This reinforces that surveillance should remain risk-based rather than population-wide. (Jacobs et al., Lancet 2021)

⚠️ Symptom Awareness & Checker

Symptom-based detection is critical since early screening is impractical. Select all symptoms present for ≥12 days/month for the past 12 months.

🚨

Clinical Alert: Ovarian cancer symptoms are often vague and non-specific. The "Index of Suspicion" rule: symptoms that are NEW, FREQUENT (>12 days/month), and PERSISTENT (>12 months) warrant urgent investigation. Delay in diagnosis averages 9–12 months from symptom onset.

🔍 Select Presenting Symptoms (Tick all that apply)

🤰

Abdominal Bloating

Persistent fullness, distension

🎯

Pelvic / Abdominal Pain

New or changed pain pattern

🍽️

Early Satiety

Feeling full after small meals

🚿

Urinary Urgency / Frequency

New increased need to urinate

⚖️

Unintentional Weight Loss

>5% body weight in 6 months

😫

Fatigue / Tiredness

New, unexplained fatigue

🔄

Bowel Changes

Constipation, diarrhoea changes

🩸

Postmenopausal Bleeding

Any bleeding after menopause

💔

Dyspareunia

Pain during intercourse

🫁

Breathlessness

Pleural effusion sign

🌊

Abdominal Swelling

Ascites, increasing waist size

🦴

Back Pain

New or worsening low back pain

Symptom Duration

Symptom Frequency

📊 Ovarian Cancer Symptom Index (OCSI) — Validated Tool

Symptom	Frequency Threshold	Duration Threshold	Clinical Significance
Bloating	>12 days/month	>12 months	High
Pelvic/abdominal pain	>12 days/month	>12 months	High
Difficulty eating / early satiety	>12 days/month	>12 months	High
Urinary symptoms	>12 days/month	>12 months	High
Fatigue	Persistent	>3 months	Moderate
Back pain	Persistent	>3 months	Moderate

📚

Goff et al. (2007) OCSI: Women with ≥1 OCSI symptom occurring >12×/month for <1 year had significantly higher prevalence of ovarian cancer. Sensitivity: 57% (early) to 80% (late-stage).

📋 Interpretation, Decision Pathways & Referral

Clinical decision-support algorithms aligned with RCOG (GTG No. 34), NICE NG12, ACOG PB #174, and Indian FOGSI guidelines.

🚨 Urgent Referral Criteria (2-Week Wait)

Postmenopausal woman with pelvic mass (any size)
CA-125 ≥35 U/mL in postmenopausal woman
Premenopausal woman: CA-125 >200 U/mL
Ascites (new or unexplained)
TVUS: solid/mixed mass with irregular borders, bilateral lesions, papillary projections
RMI (Risk of Malignancy Index) >200
ROMA score: high-risk category
Persistent symptoms on OCSI (>12×/month for >1 year)
Rapidly enlarging adnexal mass

🧮 RMI — Risk of Malignancy Index Calculator

RMI = U × M × CA-125 (Jacob et al., 1990; Validated by RCOG)

Ultrasound Score (U) Features: multilocular, solid areas, bilateral, ascites, metastases

Menopausal Status (M)

CA-125 value (U/mL)

🗺️ Clinical Decision Algorithm

🔷 Adnexal Mass / Suspicious Symptoms Detected

↓

📋 Step 1: Assess RMI, CA-125, TVUS findings, menopausal status

↓

✅ RMI <25
Low risk — manage in primary/general gynae; repeat USS in 4–6 weeks

⚠️ RMI 25–200
Moderate — refer to gynae oncologist; MRI pelvis; repeat markers

↓

🚨 RMI >200 / ROMA High / Solid Mass
URGENT referral to gynecologic oncologist — multidisciplinary team review

↓

🏥 Surgical Staging / Histopathology
Laparotomy / laparoscopy for definitive diagnosis and FIGO staging

🏥 Further Investigations Post-Referral

Investigation	Indication	Priority
MRI Pelvis (contrast)	Indeterminate mass on TVUS	Urgent
CT Chest/Abdomen/Pelvis	Suspected malignancy, staging	Urgent
PET-CT	Recurrence, rising CA-125	Elective
Diagnostic laparoscopy	Unresolved mass, staging	Urgent
Ascitic tap / cytology	Ascites present	Urgent
Tumour biopsy (CT-guided)	Unresectable disease	Urgent
BRCA testing	All new epithelial OC diagnoses	Standard

📅 Follow-Up Intervals (Post-Treatment & Surveillance)

Period	Frequency	Modality	Objective
Year 1–2 post-treatment	Every 3 months	Clinical exam + CA-125	Early recurrence detection
Year 3–5	Every 6 months	Clinical + CA-125 ± imaging	Long-term surveillance
>5 years (remission)	Annual	Clinical exam	Late recurrence, long-term effects
BRCA carriers (unaffected)	Every 6 months	CA-125 + TVUS (until BSOPSO)	Risk reduction surveillance
Post BSOPSO (surgical)	Annual	CA-125 (peritoneal OC risk)	Residual risk monitoring

🧬 Genetic Counseling & Testing

Genetic assessment is central to ovarian cancer prevention. NCCN, ESMO, and ACOG recommend germline testing for all women with epithelial ovarian cancer.

🧬 Indications for Genetic Testing

All women with epithelial ovarian cancer (NCCN, ESMO 2022)
First-degree relative with known BRCA1/2 mutation
Personal or family history of breast + ovarian cancer (same lineage)
Breast cancer diagnosed ≤45 years (personal or family)
Male breast cancer in family
≥3 relatives with breast/ovarian/pancreatic/prostate cancer
Ashkenazi Jewish ancestry (carrier rate 1:40)
Colorectal cancer diagnosed <50 (Lynch screening)
Endometrial cancer diagnosed <50 (Lynch screening)
Synchronous colorectal + endometrial/ovarian cancers

💬 Pre-Test Genetic Counseling Components

Detailed 3-generation pedigree (family history assessment)
Explanation of inheritance patterns (autosomal dominant for BRCA)
Discussion of test sensitivity, specificity, and limitations
Variants of Uncertain Significance (VUS) — counseling on implications
Psychological impact — anxiety, uncertainty, impact on family
Insurance implications (GINA Act protections — USA; India: limited regulation)
Cascade testing of family members if positive result
Risk reduction options: enhanced surveillance vs prophylactic surgery
Written informed consent for testing

🔬 Genes Tested & Associated Risks

Gene	Syndrome	Lifetime OC Risk	Action
BRCA1	HBOC	39–46%	BSOPSO 35–40yr; annual CA-125+TVUS
BRCA2	HBOC	12–20%	BSOPSO 40–45yr; annual CA-125+TVUS
MLH1	Lynch	10–15%	Consider annual TVUS+CA-125 from 30–35yr
MSH2	Lynch	10–15%	As above
MSH6	Lynch	1–11%	Annual surveillance from 35yr
PMS2	Lynch	<6%	Discuss individualised plan
BRIP1	—	6–12%	BSOPSO considered after childbearing
RAD51C	—	5–11%	Individualised counselling
RAD51D	—	10–14%	BSOPSO recommended
PALB2	—	Emerging data	Annual review

🏥 Risk-Reducing Surgical Options (BSOPSO)

⚕️

BSOPSO = Bilateral Salpingo-Oophorectomy. Reduces ovarian cancer risk by ~96% in BRCA1 and ~90% in BRCA2 carriers.

BRCA1: Recommend by age 35–40 (after childbearing)
BRCA2: Recommend by age 40–45
Lynch syndrome: Consider hysterectomy + BSOPSO after family completion
Discuss: surgical menopause, HRT safety, bone/cardiovascular health
HRT after BSOPSO: NOT contraindicated until natural menopause age (reduces surgical menopause effects; does not negate OC risk reduction)
Salpingectomy alone — not recommended as alternative in BRCA carriers (insufficient data)

📚 Patient Education & Counseling

Empowering women with knowledge about ovarian cancer risk, screening limitations, warning signs, and available support.

📌 What Women Should Know

Ovarian cancer has no reliable screening test for average-risk women
PAP smear does NOT detect ovarian cancer
Most cases are diagnosed at late stages (III/IV)
Symptoms are often vague and mistaken for digestive issues
Trust your body — report persistent new symptoms
Genetic testing can help identify high-risk individuals
OCPs (oral contraceptives) reduce ovarian cancer risk by ~50%

🛡️ Protective Factors

Oral contraceptives — 5yr use: 50% risk reduction; 15yr: 58%
Pregnancy & breastfeeding — each pregnancy: ~10% reduction
Tubal ligation / hysterectomy — 30–65% risk reduction
BSOPSO — >90% risk reduction in BRCA carriers
Maintaining healthy BMI (<25)
Regular physical activity
Avoiding talc-based perineal products
Non-smoking status
Mediterranean diet (evidence emerging)

⚠️ Risk Factors to Discuss

Age — risk rises steeply after 50
Family history — BRCA1/2, Lynch syndrome
Nulliparity — never having been pregnant
Hormone Replacement Therapy — long-term use (>5yr)
Endometriosis — 3× increased risk
Obesity (BMI >30)
Smoking — especially mucinous subtype
Talc use — perineal application
Early menarche / late menopause — prolonged ovulation
Infertility (unexplained)

🧠 Addressing Psychological Concerns

😟

Anxiety About Screening: Reassure that normal screening results are reliable for short-term reassurance, but cannot guarantee cancer-free status. Encourage symptom vigilance between checks.

❓

Misconceptions to Correct: "My PAP smear was normal" does NOT mean ovarian cancer has been excluded. "I have no symptoms" does NOT mean I don't have ovarian cancer (often asymptomatic early).

💬

Counseling for BRCA+ Result: Positive BRCA result does NOT mean cancer is inevitable — it means higher risk. Choices include enhanced surveillance, chemoprevention, or prophylactic surgery. Psycho-oncology referral should be offered.

🚨

"When to see a Doctor" — Teach Women: ANY new pelvic symptom persisting >3 weeks; postmenopausal bleeding; abdominal swelling; unexplained weight loss — see your gynaecologist within 2 weeks.

📱 Digital Health Tool Features for Patients

📊

Risk Dashboard

Personal risk score, trend monitoring, comparison to population baseline

📋

Symptom Tracker

Daily symptom diary, frequency tracking, automated alert when threshold reached

🔔

Screening Reminders

Push alerts for CA-125, TVUS appointments; lab result alerts

🧬

Genetic Test Guide

Pre/post-test counseling support; VUS explanation; family communication templates

🏥

Referral Navigator

Direct link to gynae-oncology units, appointment booking, teleconsult

📈

Outcomes Tracker

Screening uptake, detection rates, stage at diagnosis, population metrics

⚖️ Limitations, Ethics & Outcomes

Critical appraisal of ovarian cancer screening evidence, ethical considerations, and outcome metrics for program evaluation.

⚠️ Clinical Limitations of Screening

❌

False Positives: CA-125 elevated in many benign conditions (endometriosis, fibroids, PID, liver disease, menstruation). Risk: unnecessary surgery with operative morbidity and mortality.

🔍

False Negatives: CA-125 normal in ~50% of Stage I ovarian cancer. TVUS may miss small tumours (<1cm). Both modalities may fail in early-stage disease.

📊

Lead-Time Bias: Earlier detection does not necessarily translate to improved survival — may simply extend time with knowledge of disease. UKCTOCS showed no survival benefit at 14 years.

💰

Cost-Effectiveness: Annual CA-125 + TVUS for all postmenopausal women in UK costs ~£50,000/QALY — above accepted thresholds for routine implementation (NICE threshold: £20-30K/QALY).

⚖️ Ethical Considerations

Ethical Principle	Application to Ovarian Screening
Autonomy	Women have the right to informed decision-making; clear counseling about screening limitations is mandatory
Beneficence	Screening must demonstrate net clinical benefit; current evidence does not support population-wide screening
Non-maleficence	Avoid harm from false positives: unnecessary oophorectomy, surgical complications, anxiety, premature menopause
Justice	Equitable access to genetic testing (BRCA) regardless of economic status; rural/urban disparities in India
Informed Consent	Especially for genetic testing — implications for patient AND biological relatives
Confidentiality	Genetic results are sensitive; legal protections vary by country (GINA in USA; limited in India)
Overdiagnosis	Borderline ovarian tumours — risk of overtreatment; watchful waiting vs surgery debate

📈 Data Tracking & Outcome Metrics for Screening Programs

Process Metrics

Screening uptake rates (%)
Recall rates (requiring further testing)
False positive rate
Time-to-diagnosis from screening
Genetic testing referral rates
BSOPSO uptake in BRCA carriers

Clinical Outcome Metrics

Stage at diagnosis (I–IV)
Detection rate (cancers per 1000 screened)
Interval cancer rate
5-year overall survival rate
Disease-free survival
Surgical complication rates post screening-related surgery

Population-Level Metrics

Ovarian cancer mortality rate (per 100,000)
Stage shift (proportion Stage I at diagnosis)
Cost per cancer detected
Cost per QALY gained
Reduction in emergency presentations
Psychological impact (anxiety scores)

🔬

UKCTOCS (2021) — Key Findings: The largest ovarian cancer screening RCT (N=202,638). Multimodal screening detected more Stage I/II cancers (39.2% vs 24.5%) compared to no screening, representing a significant stage shift. However, 14-year follow-up did not demonstrate a statistically significant reduction in mortality (p=0.58). Longer follow-up and subgroup analyses are ongoing.

🎓 Ovarian Cancer Screening — MCQ Assessment

20 multiple-choice questions based on international clinical guidelines (ACOG, RCOG, NCCN, FIGO, NICE). Test your knowledge!

Question 1 of 20 Score: 0 / 0

QUESTION 1 OF 20

🏆

Gynaeguru: Ovarian Cancer Risk Assessment & Screening Tool

Quiz Complete!